Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.

Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.

In 2014, the U.S. National Institutes of Health launched a program called the Undiagnosed Disease Network. The New England Journal of Medicine published a study looking at the results of the network.